Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276036 · ClinicalTrials.gov registry record · NA
Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.
A NA study of Cytopenia, sponsored by Meyer Children's Hospital IRCCS.
- Active
- Registry status
- NA
- Development phase
- 53
- Enrollment target
- 6
- Study locations
NCT06276036 is a NA study of Cytopenia that is active but no longer recruiting, run by Meyer Children's Hospital IRCCS. The registered enrollment target is 53 participants, below the 374-participant average among 11 other Cytopenia trials with a reported enrollment target (86% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT06276036, a NA study of Cytopenia, is active but no longer recruiting, sponsored by Meyer Children's Hospital IRCCS.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
- 6
- Study locations
Study Summary
Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopenias has not yet been fully elucidated. Moreover, conventionally employed therapeutic strategies often fail, leading to increased healthcare costs, high morbidity, and even mortality. Therefore, there is a need to establish clinical guidelines for diagnosis and to identify early biomarkers capable of identifying individuals responsive to therapy. Thus, a systematic approach to the study of such pathologies will allow for the identification of early biomarkers and facilitate the development of targeted therapeutic strategies
Conditions Studied
Interventions
- OTHER Identification of specific markers
Study Locations (6)
Other
- Ghent University Hospital - Ghent
- Clinica Pediatrica - Università di Catania - Catania
- Meyer Children's Hospital IRCCS - Florence
- IRCCS Istituto Giannina Gaslini - Genova
- Azienda Ospedaliero Universitaria Pisana - Pisa
Florida
- University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2025-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06276036
The ClinicalTrials.gov registry entry for NCT06276036 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 11 other Cytopenia trials with a reported enrollment target (86% lower). The listed sponsor is Meyer Children's Hospital IRCCS, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytopenia appearing as the primary indexed condition, and to 1 intervention - of which Identification of specific markers is the first listed.
NCT06276036 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06276036 about?
NCT06276036 is a clinical study titled "Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.". Autoimmune cytopenias resistant to treatment are among the most common clinical manifestations observed in patients with congenital alterations of the immune system, such as primary immunodeficiencies (PI). The exact contribution of immune system alterations to the pathogenesis of autoimmune cytopen...
What is the current status of trial NCT06276036?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 53 participants. The study started on 2019-07-23. Estimated completion is 2025-06-01.
What conditions does trial NCT06276036 study?
This clinical trial studies the following conditions: Cytopenia.
What interventions are being tested in trial NCT06276036?
The interventions under investigation include: Identification of specific markers (OTHER).
Who is sponsoring clinical trial NCT06276036?
This trial is sponsored by Meyer Children's Hospital IRCCS, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06276036 being conducted?
This trial has 6 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
ACTIVE NOT RECRUITING · NA
-
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies
ACTIVE NOT RECRUITING · NA
-
Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study
RECRUITING
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Early Intervention in High Risk CCUS
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.